Rivaroxaban, a new oral factor Xa inhibitor, provides new data on anticoagulation

Author： Siddique Aurangzeb   Lip Gregory YH   Shantsila Eduard  

Publisher： Future Medicine

ISSN： 1475-0708

Source： Therapy, Vol.6, Iss.2, 2009-03, pp. : 187-189

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 79, Iss. 5, 2015-05 ,pp. : 838-846

John Wiley & Sons Inc

Access to resources Recommend Favorite

Measuring Quality of Oral Anticoagulation Care: Extending Quality Measurement to a New Field

By Rose Adam J.   Berlowitz Dan R.   Frayne Susan M.   Hylek Elaine M.  

Joint Commission Journal on Quality and Patient Safety, Vol. 35, Iss. 3, 2009-03 ,pp. : 146-155

Joint Commission Resources

Access to resources Recommend Favorite

New insights into the biology of tissue factor pathway inhibitor

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. S1, 2015-06 ,pp. : S200-S207

John Wiley & Sons Inc

Access to resources Recommend Favorite

New oral anticoagulant drugs: real-world data

By Iqbal Omer  

Personalized Medicine, Vol. 10, Iss. 5, 2013-07 ,pp. : 419-422

Future Medicine

Access to resources Recommend Favorite

Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re‐appraisal

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. S1, 2015-06 ,pp. : S187-S194

John Wiley & Sons Inc

Access to resources Recommend Favorite